PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast

International Journal of COPD

Volumn 2, Issue 2, 2007, Pages 121-129

  Boswell Smith, Victoria ^a   Spina, Domenico ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cilomilast; COPD; Inflammation; Neutrophil; PDE4; Roflumilast

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIOXIDANT; ANTITUSSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IPRATROPIUM BROMIDE; METHYLXANTHINE DERIVATIVE; MUCOLYTIC AGENT; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PROSTAGLANDIN E2; RESPIRATORY STIMULANT AGENT; ROFLUMILAST; ROLIPRAM; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; VASODILATOR AGENT; WARFARIN;

ALLERGIC ASTHMA; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIINFLAMMATORY ACTIVITY; ARTERY DISEASE; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMPHYSEMA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; GENETIC RISK; HUMAN; MONOTHERAPY; NAUSEA; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; SMOKING CESSATION;

AMINOPYRIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; DIARRHEA; HUMANS; LUNG; NAUSEA; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS; TREATMENT OUTCOME; VOMITING;

EID: 34547700771     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. [SRBS] A statistics Report from the British Society. 2006. The burden of lung disease [online]. Accessed September 20, 2006. URL: http://www.brit-thoracic.org.uk/BurdenofLungDisease2.html.
2. Altana. 2005. Top line results of first one year study with Daxas [online]. Accessed September 20, 2006. URL: http://www.altana.com/root/ index.php?page_id=202&cms_press_id:355.
3. Barnes PJ, Shapiro SD, Pauwels RA. 2003. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J, 4:672-88.
4. Barnes PJ, Stockley RA. 2005. COPD: current therapeutic interventions and future approaches. Eur Respir J, 6:1084-106.
5. Bateman ED, Holmes M, Muir JF, et al. 2004. Safety profile of roflumilast, a novel, selective phosphodiesterase4 inhibitor, in patients with moderate to severe COPD. Am J Respir Crit Care Med, A596.
6. Bergeron C, Boulet LP. 2006. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest, 4:1068-87.
7. Boswell-Smith V, Spina D, Oxford AW, et al. 2006. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2 (2,4,6-trimethylphenylimino)- 3-(n-carbamoyl-2- aminoethyl)-3,4,6,7- tetrahydro-2H-pyrimido[6,1-a] isoquinolin-4-one] and RPL565 [6,7-dihydro-2- (2,6-diisopropylphenoxy)-9,10-dimethoxy- 4H-pyrimido [6,1-a]i soquinolin-4-one]. J Pharmacol Exp Ther, 2:840-8.
8. Boszormenyi-Nagy G, Pieters WR, Steffen H, et al. 2005. The effect of roflumilast treatment and subsequent withdrawal in patients with COPD. Proc Am Thorac Soc, A544.
9. Bundschuh DS, Eltze M, Barsig J, et al. 2001. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther, 1:280-90.
10. Cherry JA, Davis RL. 1999. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement and affect. J Comp Neurol, 407:287-301.
11. Churg A, Wang RD, Tai H, et al. 2004. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med, 5:492-8.
12. Churg A, Zay K, Shay S et al. 2002. Acute cigarette smoke-reduced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Am J Respir Cell Mol Biol, 3:368-74.
13. David ME, Zech K, Seiberling A, et al. 2004. Roflumilast, a novel, oral, selective PDE4 inhibitor, shows high absolute bioavalability. J Allergy Clin Immunol, 2:780.
14. Dent G, White SR, Tenor H, et al. 1998. Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm Pharmacol Ther, 1:47-56.
15. Derian CK, Santulli RJ, Rao PE, et al. 1995. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J Immunol, 1:308-17.
16. Ellis JL, Undem BJ. 1994. Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi. Am J Respir Crit Care Med, 1:118-22.
17. Engelstatter R, Wingertzahn M, Schmid-Wirlitsch C, et al. 2005. Roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor, does not exhibit bronchodilatory activity. Ann Allergy Asthma Immunol, 1:159.
18. Essayan DM. 2001. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol, 5:671-80.
19. Fuhrmann M, Jahn HU, Seybold J, et al. 1999. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol, 2:292-302.
20. Gamble E, Grootendorst DC, Brightling CE, et al. 2003. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 8:976-82.
21. Giembycz MA. 2006. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol, 2:138-52.
22. Grootendorst DC, Gauw SA, Sterk PJ, et al. 2005. Treatment with PDE4 Inhibitor Roflumilast Reduces Sputum Neutrophil and Eosinophil Numbers in Patients with COPD. Proc Am Thorac Soc A543.
23. Hatzelmann A, Schudt C. 2001. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther, 1:267-79.
24. Hauns B, et al. 2003. Investigation of pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single morning or evening oral administration of 500æg roflumilast in healthy subjects - an open, randomised, two-period crossover study. Am J Respir Crit Care Med, 7:A92.
25. Hogg JC. 2004. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet, 9435:709-21.
26. Houslay MD. 2001. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol, 249-315.
27. Hunnemeyer A, et al. 2002a. No interaction of roflumilast and its active metabolite, roflumilast N-oxide, with inhaled budesonide. Am J Respir Crit Care Med, 8.
28. Hunnemeyer A, Hauns B, Drollman A, et al. 2002b. Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide is not influenced by smoking. Am J Respir Crit Care Med, 8:A594.
29. Ito K, Ito M, Elliott WM, et al. 2005. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med, 19:1967-76.
30. Jin SL, Conti M. 2002. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA, 11:7628-33.
31. Jones NA, Boswell-Smith V, Lever R, et al. 2005. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther, 2:93-101.
32. Keatings VM, Collins PD, Scott DM, et al. 1996, Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med, 2:530-4.
33. Kohyama T, Liu X, Zhu YK, et al. 2002. Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase. Am J Respir Cell Mol Biol, 4:487-94.
34. Kumar RK, Herbert C, Thomas PS, et al. 2003. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther, 1:349-55.
35. Kwak HJ, Song JS, Heo JY, et al. 2005. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther, 3:1188-95.
36. Lamontagne S, Meadows E, Luk P, et al. 2001. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res, 1-2:84-96.
37. Landells LJ, Szilagy CM, Jones NA, et al. 2001. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol, 5:722-9.
38. Leclerc O, Lagente V, Planquois JM, et al. 2006. Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J, 6:1102-9.
39. Leichtl S, et al. 2002a. Efficacy of once-daily roflumilast, a new, orally active selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, A229.
40. Leichtl S, et al. 2002b. Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with Chronic Obstructive Pulmonary Disease. Eur Respir J, (Suppl 38): P303s.
41. Lenfant C, Khaltaev N. 2005. Workshop report: Global strategy for the diagnosis, management, and prevention of COPD [online]. Accessed September 20, 2006. URL: http://www.goldcopd.org/ Guidelineitem.asp?11=2&12=1&intId=989.
42. Lipworth BJ. 2005. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, 9454:167-75.
43. Losco PE, Evans EW, Barat SA, et al. 2004. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol Pathol, 3:295-308.
44. Martin-Chouly CA, Astier A, Jacob C, et al. 2004. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci, 7:823-40.
45. Martorana PA, Beume R, Lucattelli M, et al. 2005. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med, 7:848-53.
46. Mata M, Sarria B, Buenestado A, et al. 2005. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax, 2:144-52.
47. Pauwels RA, Buist AS, Calverley PM, et al. 2005. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med, 5:1256-76.
48. Perez-Torres S, Miro X, Palacios JM, et al. 2000. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat, 3-4:349-74.
49. Profita M, Chiappara G, Mirabella F, et al. 2003. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8 and GM-CSF release from airway cells of patients with COPD. Thorax, 7:573-9.
50. Rabe KF, Bateman ED, O'Donnell D, et al. 2005. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 9485:563-71.
51. Rennard SI, Schachter N, Strek M, et al. 2006. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest, 1:56-66.
52. Retamales I, Elliott WM, Meshi B, et al. 2001. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med, 3:469-73.
53. Sanz MJ, Cortijo J, Morcillo EJ. 2005. PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther, 3:269-97.
54. Schmidt DT, Watson N, Dent G, et al. 2000. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. Br J Pharmacol, 8:1607-18.
55. Shapiro SD. 2001. End-stage chronic obstructive pulmonary disease: the cigarette is burned out but inflammation rages on. Am J Respir Crit Care Med, 3:339-40.
56. Shapiro SD, Goldstein NM, Houghton AM, et al. 2003. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol, 6:2329-35.
57. + T-Lymphocytes. Mol Pharmacol, 66:1679-89.
58. Spina D 2004. The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflamm Allergy, 3:231-6.
59. Spond J, Chapman R, Fine J, et al. 2001. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther, 2:15-64.
60. Stoller JK, Aboussouan LS. 2005. Alpha1-antitrypsin deficiency. Lancet, 9478:2225-36.
61. Sturton G, Fitzgerald M. 2002. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest, 5 Suppl:192S-6S.
62. Takahashi M, Terwilliger R, Lane C, et al. 1999. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci, 2:610-8.
63. Van Schalkwyk E, Strydom K, Williams Z, et al. 2005. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol, 2:292-8.
64. Weimar C, Bethke T, Westphal K, et al. 2002. Roflumilast and its active metabolite, roflumilast N-oxide, do not interact with inhaled salbutamol. Am J Respir Crit Care Med, 8:A594.